SEARCH:   Advanced

Blood, 1 August 2006, Vol. 108, No. 3, pp. 836-846. Prepublished online as a Blood First Edition Paper on April 4, 2006; DOI 10.1182/blood-2005-11-4503. This Article Full Text (PDF) All Versions of this Article: 2005-11-4503v1 108/3/836    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Martino, R. Articles by De Witte, T. Search for Related Content PubMed PubMed Citation Articles by Martino, R. Articles by De Witte, T. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 15, 2005 Accepted March 3, 2006 Retrospective comparison of reduced intensity conditioning and conventional high dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes Rodrigo Martino*, Simona Iacobelli, Ronald Brand, T. Jansen, Anja van Biezen, J. Finke, Andrea Bacigalupo, D. Beelen, J. Reiffers, A. Devergie, E. Alessandrino, G.J. Mufti, R. Barge, Jorge Sierra, T. Ruutu, M. Boogaerts, M. Falda, J.P. Jouet, Dieter Niederwieser, and Theo De Witte Division of Clinical Hematology, Hospital de la Sant Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain Department of Medical Statistics, University of Leiden, Leiden, The Netherlands Chronic Leukemia Working Party Registry Leiden, Leiden, The Netherlands Department of Medicine, Hematology, and Oncology, University of Freiburg, Freiburg, Germany Department of Hematolo, Ospedale San Martino, Genova, Italy Department of Bone Marrow Transplantation, University Hospital, Essen,, Essen, Germany CHU Bordeaux, Hopital Haut-Leveque, Pessac, France Department of Hematology, Hopital St. Louis, Paris, France Policlinico San Matteo IRCCS, Pavia, Italy Department of Haematology, Kings College London School of Medicine, London, United Kingdom Department of Hematology, LUMC, Leiden, The Netherlands Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland Department of Hematology, University Hospital of Leuven, Leuven, Belgium Centro Trapianti Midollo, Azienda Ospedaliera S. Giovanni, Torino, Italy Service de Maladies du Sang, Hopital Claude Huriez, Lille, France Department Internal Medicine, University Hospital Leipzig, Leipzig, Germany Department of Hematology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands * Corresponding author; email: rmartino{at}santpau.es. In this multicenter retrospective study, the outcomes of 836 patients with myelodysplastic syndrome (MDS) who underwent transplantation with an HLA-identical sibling donor were analyzed according to two types of conditioning: reduced-intensity conditioning (RIC) in 215 patients, and standard myeloablative (or high dose) conditioning (SMC) in 621 patients. In multivariate analysis, the 3-year relapse rate was significantly increased after RIC (HR, 1.64; 95% CI, 1.2-2.2; P= 0.001), but the 3-year NRM was decreased in the RIC group (HR,0.61; 95% CI, 0.41-0.91; P= 0.015). The 3-year probabilities of progression-free and overall survivals were similar in both groups (39% after SMC vs. 33% in RIC; multivariate P=0.9; and 45% vs. 41%, respectively; P=0.8). In conclusion, the lower 3-year NRM after RIC is encouraging, since these patients were older (age >50 years in 73% RIC vs. 28% in SMC, p<0.0001) and had more adverse pre-transplant variables. However, based on the higher risk of relapse, patients with no contraindications for SMC should not receive a RIC outside of prospective randomized trials, which are needed to establish the position of RIC-based transplantation in the treatment of patients with MDS. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: RIC for MDS: the glass is half full David L. Porter Blood 2006 108: 780-781. [Full Text] [PDF] This article has been cited by other articles: Z. Lim, R. Brand, R. Martino, A. van Biezen, J. Finke, A. Bacigalupo, D. Beelen, A. Devergie, E. Alessandrino, R. Willemze, et al. Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia J. Clin. Oncol., January 20, 2010; 28(3): 405 - 411. [Abstract] [Full Text] [PDF] A. Tefferi and J. W. Vardiman Myelodysplastic Syndromes N. Engl. J. Med., November 5, 2009; 361(19): 1872 - 1885. [Full Text] [PDF] C. Kyriakou, C. Canals, J. Finke, G. Kobbe, J.-L. Harousseau, H.-J. Kolb, N. Novitzky, A. H. Goldstone, A. Sureda, and N. Schmitz Allogeneic Stem Cell Transplantation Is Able to Induce Long-Term Remissions in Angioimmunoblastic T-Cell Lymphoma: A Retrospective Study From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J. Clin. Oncol., August 20, 2009; 27(24): 3951 - 3958. [Abstract] [Full Text] [PDF] H. E. Kohrt, B. B. Turnbull, K. Heydari, J. A. Shizuru, G. G. Laport, D. B. Miklos, L. J. Johnston, S. Arai, W.-K. Weng, R. T. Hoppe, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors Blood, July 30, 2009; 114(5): 1099 - 1109. [Abstract] [Full Text] [PDF] N. Kroger, R. Brand, A. van Biezen, A. Zander, J. Dierlamm, D. Niederwieser, A. Devergie, T. Ruutu, J. Cornish, P. Ljungman, et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation Haematologica, April 1, 2009; 94(4): 542 - 549. [Abstract] [Full Text] [PDF] E. Jabbour, H. Kantarjian, D. Jones, M. Breeden, G. Garcia-Manero, S. O'Brien, F. Ravandi, G. Borthakur, and J. Cortes Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy Blood, July 1, 2008; 112(1): 53 - 55. [Abstract] [Full Text] [PDF] N. Kroger Epigenetic Modulation and Other Options to Improve Outcome of Stem Cell Transplantation in MDS Hematology, January 1, 2008; 2008(1): 60 - 67. [Abstract] [Full Text] [PDF] M. L. Sorror, B. M. Sandmaier, B. E. Storer, M. B. Maris, F. Baron, D. G. Maloney, B. L. Scott, H. J. Deeg, F. R. Appelbaum, and R. Storb Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation J. Clin. Oncol., September 20, 2007; 25(27): 4246 - 4254. [Abstract] [Full Text] [PDF] D. Blaise, N. Vey, C. Faucher, and M. Mohty Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia Haematologica, April 1, 2007; 92(4): 533 - 541. [Abstract] [Full Text] [PDF] C. A. Schiffer Clinical Issues in the Management of Patients with Myelodysplasia Hematology, January 1, 2006; 2006(1): 205 - 210. [Abstract] [Full Text] [PDF] B. L. Scott and B. M. Sandmaier Outcomes with Myeloid Malignancies Hematology, January 1, 2006; 2006(1): 381 - 389. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020